13th Sep 2007 07:02
AstraZeneca PLC13 September 2007 AstraZeneca launches and prices a EUR750 million debut eurobond AstraZeneca PLC, rated A1 (stable) by Moody's and AA- (stable) by Standard &Poor's, yesterday priced a successful debut eurobond transaction (the "Bonds")issuing a total of EUR750 million. The proceeds of the issue will be used forgeneral corporate purposes and to repay a portion of the outstanding UScommercial paper taken on in connection with the acquisition of MedImmune. The transaction is issued off a new Euro Medium Term Note (EMTN) programme,dated September 10th 2007, and is a EUR750 million, fixed rate issue with acoupon of 5.125% maturing in January 2015. "This transaction represents a further part of our refinancing of theacquisition of MedImmune Inc, following our successful $6.9bn, 4-tranche SECGlobal issue last week. As with last week's issue, this transaction representsan enhancement of our financial flexibility by diversifying further our sourcesof funding. We undertook an extensive roadshow of investor meetings in London,Paris and Frankfurt and are very pleased with the feedback on the AstraZenecacredit, and the reception for us in the bond markets", said David Brennan, ChiefExecutive Officer of AstraZeneca. The Bonds will be issued to institutional investors outside the US in accordancewith Regulation S of the U.S. Securities Act 1933. The Bonds will be admittedto listing on the UKLA's Official List and to trading on the London StockExchange's Fixed Income and Gilt Edged Market. About AstraZeneca AstraZeneca is a major international healthcare business engaged in theresearch, development, manufacture and marketing of prescription pharmaceuticalsand the supply of healthcare services. It is one of the world's leadingbio-pharmaceutical companies with healthcare sales of $26.47 billion and leadingpositions in sales of gastrointestinal, cardiovascular, neuroscience,respiratory, oncology and infection products. AstraZeneca is listed in the DowJones Sustainability Index (Global) as well as the FTSE4Good Index. 13 September 2007 Media Enquiries: Edel McCaffrey, Tel: +44 (0) 207 304 5034 Steve Brown, Tel: +44 (0) 207 304 5033 Investor Relations: Mina Blair, Tel: +44 (0) 207 304 5084 Jonathan Hunt, Tel: +44 (0) 207 304 5087 Karl Hard, Tel: +44 (0) 207 304 5322 Jorgen Winroth, Tel: +1 (212) 579 0506 Ed Seage, Tel: +1 302 886 4065 Pete Vozzo, (MedImmune) Tel: + 1 301-398-4358 This announcement is for information only and does not constitute an offer orinvitation to subscribe for or purchase any securities. The securities have not been registered under the U.S. Securities Act of 1933,as amended (the "Securities Act"), and no securities shall be offered or sold inthe United States or to U.S. persons (as those terms are defined in Regulation Sunder the Securities Act) unless an exemption from the registration requirementsof the Securities Act is available. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Astrazeneca